Introduction: Basal cell carcinoma (BCC) is the most common form of skin cancer; however,
Telephone interviews lasted between 60 and 90 mins.
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Results: Thirty-four interviews were conducted (G1: N = 13; G2: N = 21). The majority of patients were aged either 55-64 years (32%, N = 11) or 76? years (32%, N = 11) and were primarily male (82%, N = 28); most (75%, 
INTRODUCTION
Basal cell carcinoma (BCC) is the most common cancer among fair-skinned individuals, with a wide range in age-standardized annual incidence by country from approximately 44-745 per 100,000 for women and 54-1041 per 100,000
for men in Germany and Australia, respectively [1] [2] [3] . The incidence of non-melanoma skin cancer (NMSC), and specifically BCC, is increasing worldwide. The incidence of NMSC procedures in the USA has almost doubled since 1994, and the total number of new cases in 2006 was estimated at 3.5 million per year, approximately 80% of which were BCC [4] . By 2030, it is anticipated that the number of cases presenting to dermatologists could increase by an estimated 50% [5] . Given that primary BCCs occur mostly on the areas of the body with the greatest sun exposure, approximately 70% occur on the head or face [6] . Less than 5% of all BCC cases become locally advanced or metastatic [7] .
However, if untreated, these lesions can cause substantial local tissue destruction and disfigurement [8] . Most BCC lesions can be removed through surgical measures; however, a small percentage of patients are unsuitable for surgery (because of the location or size of the lesion) or develop a more advanced stage of disease. These patients constitute a poorly defined (but small) percentage of overall BCC [9] and might have a greater disease impact [10] .
Although several efforts have been made to determine the impact of NMSCs on the health-related quality of life (HRQL) of patients [11] [12] [13] [14] , few studies have examined the specific impact of BCC. Patient-reported outcome (PRO) measures, such as the Skindex, Dermatology Life Quality Index (DLQI), and Short-form Health Survey-12 (SF-12), have been administered in studies of NMSC; however, these measures were designed to evaluate more general aspects of HRQL for non-cancer skin conditions [13, 15, 16] . Rhee et al. [17] developed and validated the Skin Cancer Index (SCI) to address the need for a disease-specific HRQL instrument in NMSC; however, their study population was not BCC specific and only focused on patients who experienced skin cancer in the cervicofacial region. Burdon-Jones et al. [18] recognized and attempted to address the lack of knowledge related to non-metastatic skin cancer PRO measures by eliciting general opinions in writing from patients with malignant melanoma and NMSC, and concluded that a disease-specific measure for patients with both metastatic and non-metastatic disease was needed. Shingler et al. [10] conducted a health utility study that found that severe forms of BCC can represent a significant psychological and cosmetic burden to patients, but these results were quantitative and did not give patients the opportunity to describe the burden in their own words. A recent study by Mathias et al. [19] , undertaken to develop a BCC-specific PRO measure, found more substantial impacts related to daily activities and psychosocial effects in patients with more advanced stages of disease (locally advanced, metastatic BCC) compared with patients with basal cell nevus syndrome. However, consistent with Shingler et al. [10] , Mathias et al. [19] This parallel interview study was terminated early because of a lack of enrollment, but the data from the two interviews were included in the current analysis. Institutional review board (IRB) approval was obtained before the start of the study and all procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013, and Good Clinical Practices. All patients provided written informed consent before the start of the interview.
Patient Recruitment
Patients were identified from patient databases or medical records at each clinical site or through participation in the ongoing clinical trial (ClinicalTrials.gov #NCT01226485). All patients were required to be aged 18 years or older, be able to participate in a telephone interview in English, and have the presence of measurable disease at the time of screening as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). All patients had active disease that was either newly diagnosed or recurrent; G1 had been diagnosed with non-advanced BCC (including only superficial or nodular histology) and all patients in G2 had a diagnosis of BCC that was locally advanced or metastatic [20] . There were no restrictions based on location of the patients' lesion(s) for participation in the study. Patients were not eligible if they had a clinically relevant medical or psychiatric condition that, in the opinion of the investigator or site coordinator, would interfere with the patient's ability to complete the study.
Data Collection
All patients were screened over the telephone by site coordinators for inclusion in the study. approach, the data were examined for general themes, as well as specific issues and concerns associated with BCC symptoms and impacts, with a focus on words or phrases that patients used to describe symptoms associated with the condition. All patient data for the analysis were deidentified before review by the sponsor of the study and co-authors.
RESULTS

Clinical and Demographic Characteristics
Thirty-four patient interviews were conducted (G1: N = 13; G2: N = 21). G1 comprised 11 patients with superficial subtype and two patients with nodular subtype BCC. G2 comprised 12 patients with metastatic BCC and nine patients with locally advanced BCC.
Importantly, as data were collected, similar trends were observed in patient responses at an earlier time point for patients with non-advanced disease versus advanced disease; as a result, a smaller number of patients were recruited in G1.
The overall sample was mostly split between patients aged 55-64 years (32%, N = 11) and those aged 76? years (32%, N = 11), and comprised primarily men (82%, n = 28). In G1, most patients (77%, N = 10)
were older than 65 years, whereas, in G2, approximately half (48%, N = 10) were aged 55-64 years (Table 1 ). Almost half of the patients (47%, N = 16) were married or living with a partner and most patients (53%, N = 18) were retired or disabled. All patients had some form of health insurance, with more than half (59%, N = 20) using Medicare for coverage. Approximately half (56%, N = 19) reported having lived in a 'high-sun' area when they were 10-20 years old, although a greater proportion of patients in G1 (92%, N = 12) communicated that they were exposed to sun 'a lot' during that time compared with patients in G2 (57%, N = 12).
A high-sun area was not defined by geographical location, but rather was based on patient self-report and investigator discretion. Although more patients in G1 (69%, N = 9) reported having frequent sunburns when younger, fewer in G1 (38%, N = 5) reported having skin that burned easily compared with those in G2 (47%, N = 9).
Treatment History
Across both groups, most patients (84%, N = 27) had received pharmacologic therapy or had undergone procedures for BCC before the interview (Table 2) . Surgical excision (53%, N = 17) and Moh's surgery (37%, N = 12) were the most common treatments received (by at least one-third of patients in each group). Almost half of the patients in G2 (47%, N = 9) had received vismodegib at some point previously. In terms of current treatment, most patients (75%, N = 24) were receiving some form of treatment, with almost equal amounts in both groups (G1: 77%, N = 10; G2: 74%, N = 14). Of those currently receiving treatment, vismodegib was the most common pharmacologic treatment at the time of their interview (19%, N = 6), which was recorded only for patients in G2, in line with the regulatory approved indication. 
Symptoms
The symptoms reported by patients were common across groups, and almost all patients in G1 (85%, N = 11) and G2 (95%, N = 20) were experiencing at least one symptom related to their BCC at the time of the current study (Table 3) Hair loss 3 (9)
Muscle cramps 2 (6) 0 (0) 2 (9) to the lesion site (38%, n = 13), bleeding lesions (26%, N = 9), and problems sleeping (23%, N = 8). Pain related to cancer was frequently reported by G2 patients only (48%, N = 10).
At the conclusion of the interview, patients were asked which symptoms they considered the 'most bothersome'. Most patients in G2
(95%, N = 20) identified one or more symptoms as most bothersome compared with 69%
(N = 9) of patients in G1. Patients in G1
(N = 4) had greater difficulty in identifying a bothersome symptom because they either had only one symptom or did not consider their symptoms to be bothersome. Across both groups, of the 29 patients who reported at least one bothersome symptom, the most commonly reported were cancer-related stress (24%, N = 7), itching localized to the lesion (24%, N = 7), and open sores that failed to heal (14%, N = 4) ( Table 4) .
Impact
All patients were asked whether their BCC had impacted their daily activities, emotional well-being, social or leisure activities, work or studies, personal relations, or sexual activities over the previous 7 days. Table 3 summarizes this impact quantitatively.
Daily Activities
A greater proportion of patients (76%, N = 16) in G2 reported experiencing some impact on daily activities compared with those in G1 (46%, N = 6). When asked how their cancer had affected their daily activities, 31% (N = 4) of patients in G1 and 57% (N = 12) of patients in G2 mentioned having to limit activities, such as exercise, strenuous activities, such as lifting heavy objects, or outdoor activities, to avoid sun exposure.
Patients in G2 (19%, N = 4) also mentioned experiencing fatigue, which limited their ability to complete chores or other household activities, whereas patients in G1 (31%, N = 4) mentioned needing to be more cautious when doing activities as a result of surgeries or symptoms.
One patient in G1 and four patients in G2 mentioned having to change their schedules and daily activities because of doctor's appointments or when recovering from surgeries.
Emotional Well-Being
Compared with G1, a greater proportion of patients in G2 reported being emotionally impacted by the disease (G1: 46%, N = 6; G2: A few patients in G1 (15%, N = 2) and G2 (14%, N = 3) mentioned being depressed because of their cancer.
Social Impact
About half of the G2 patients (52%, N = 11) and one-third of G1 patients (31%, N = 4) reported an impact on their social or leisure activities The symptoms listed were described by patients as their most bothersome symptoms during the interview discussion Pt ID patient identifier a A denominator of 29 was used to calculate the percentages; this is based on the total number of patients who reported at least one 'most bothersome' symptom because of their cancer. The most common reasons included having to reduce outdoor activities (G1: 15%, N = 2; G2: 24%, N = 5), such as hiking, gardening, and going to watch baseball games, as well as spending less time with friends and family (G1: 23%, N = 3; G2:
24%, N = 5) because of their appearance.
Patients also reported that the time spent 
Cosmetic and Functional Impact
Cosmetic and functional impacts resulting from cancerous lesions or cancer-related surgeries were described by patients in both groups. Almost half of G2 patients (48%, N = 10) described functional and cosmetic impacts, such as visible scarring (9%, N = 2), malformation of the skin because of the cancerous lesions (24%, N = 5), or having part or all of a body part (i.e., ears or eyes) removed because of surgery (19%, N = 4). One-third of patients in G1 (31%, N = 4) were concerned with the need for repeat surgeries and the potential for scarring, especially in places on the body that were highly visible to others.
Patients across both groups also communicated a feeling of fear, stress, and embarrassment associated with the cosmetic and functional impacts.
Changes in Behavior
Changes in behavior were reported almost equally across both groups (G1: 100%, N = 13; G2: 91%, N = 10/11); limitations on sun exposure were reported most commonly (G1: 92%, N = 12; G2: 82%, N = 9/11). Almost half of the patients in both groups (G1: 38%, N = 5; Table 5 .
DISCUSSION
Although several efforts have been made to determine the impact of NMSC on HRQL, few studies have examined the specific impact of BCC. This study was conducted to generate descriptive information specific to BCC.
Importantly, patients with either non-advanced or locally advanced or metastatic BCC experienced symptoms and impacts from their disease that affected their HRQL. Although there were some commonalities between the two groups, there were some key differences that are important to highlight. Overall, a greater proportion of patients with locally advanced or metastatic disease deemed their condition to be severe compared with patients with non-advanced disease. Patients in G2 were more likely to describe frequent and bothersome symptoms and expressed experiencing a greater HRQL impact across six of the seven categories evaluated compared with patients in G1. Pain related to cancer was reported by approximately half of G2 patients, whereas it was not reported by any patient in G1. Similar to Mathias et al. [19] , the current study found that impacts on emotional well-being and daily activities were common and more frequently reported in patients with more advanced disease. Consistent with Shingler et al. [10] , the current study also found that BCC imposes a significant psychological and cosmetic burden on patients, as demonstrated by approximately 50% of G2 experiencing visible scarring, malformation of the skin, or loss of a body part.
Although more subtle, disease stages that are non-advanced can impose bothersome sequelae and negative impacts on patients' HRQL. Despite the relatively small sample size of G1, approximately half of patients reported the disease as having a negative impact on their emotional well-being and daily activities. In addition, anxiety related to potential or existing scarring, as well as tumor recurrence, was communicated by one-third of the sample.
These findings, similar to those of Burdon-Jones et al. [18] , suggest that, although the burden can be less when compared with those with more advanced disease, it is important to assess HRQL in all patients with BCC. In our study, the domains or themes that emerged as the most important to assess a patient's HRQL across both groups included cosmetic and functional impacts, emotional well-being, and changes in behavior and daily activities to avoid sun exposure. These domains, particularly the fear of scaring and disfigurement and the importance of avoiding excess sun, also corresponded to the important themes identified by Burdon-Jones et al. [18] , providing additional evidence to support the impact of these domains in the BCC patient population.
In addition, the findings from this study also suggest that, although is it important to evaluate the HRQL in both groups of patients, different aspects of the HRQL domains are more relevant based on the stage of the disease. For example, the impact on daily activities is an important domain to measure in both populations. Most patients with non-advanced disease experienced cutaneous surface-level symptoms, such as red spots or localized itching, which tended to affect daily activities that pertained to limiting sun exposure or modifying clothing selections. However, in patients with more advanced disease, the daily activities affected were changes in lifestyle, such as the inability to clean the house or reductions in exercise. Based on these differences, PROs in the local disease population should focus on these initial behavioral changes in terms of daily impact, whereas patients with advanced disease should be more broadly assessed, given the number of activities limited by their condition.
In addition, because of the number of patient comments regarding healthcare utilization and time burden, it would be useful to examine the healthcare resource utilization in both patient groups to gain a better understanding of the economic and time burden associated with BCC. Many patients were currently undergoing treatment at the time of the interviews, and both patient groups mentioned the burden associated with treatment, such as scheduling appointments, the cost of the procedures, and reduced or loss of productivity while recovering from surgery.
Although the study was intended to characterize the patient population, several limitations should be considered when interpreting these results. Patients for both groups were difficult to recruit. 
